Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 20/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939715 | 0.93 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4585222 | 0.92 | ADRB3 (0.79) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4585227 | 0.92 | ADRB3 (0.79) | ADRB3ADRB1ADRB2 | |
| SCHEMBL1940238 | 0.88 | ADRB3 (0.81) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4586447 | 0.87 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4586449 | 0.87 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 | |
| SCHEMBL1939614 | 0.86 | ADRB3 (1.00) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4467680 | 0.85 | ADRB3 (0.98) | ADRB3ADRB1ADRB2 | |
| Hydrochloric Acid SCHEMBL4478546 | 0.82 | ADRB3 (0.78) | ADRB3ADRB1ADRB2 | |
| SCHEMBL5703962 | 0.81 | ADRB3 (0.80) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074086-B1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2010-09-23 | — | — | US | disclosed |
| EP-2074086-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008048609-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240653-A1 | BIPHENYL SULFONYL AND PHENYL-HETEROARYL SULFONYL MODULATORS OF THE HISTAMINE H3-RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HRH3, HRH4, HRH1 | ADRB3 158/4885ADRB1 185/4885ADRB2 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.